2025-02-18T10:26:53-08:00 2024-05-31 872635810 Tovella Dowling PC 600 W Broadway Ste 660 San Diego San Diego CA 92101 990 2023-06-29 932180352 Panoplia Laboratories Inc PANO 5854878218 245 First Street 6th Floor Cambridge MA 02142 Brian Wang Vice President 2025-02-18 true true Julie U Nguyen Esq P01881055 6199309332 2023 2025-03-06 01:10:19Z X Brian Wang 245 First Street 6th Floor Cambridge MA 02142 854335 false X panoplialabs.org X 2023 DE To eliminate the risks posed by pandemic threats through the advancement of science and innovation in medical countermeasure development, ensuring the health and well-being of individuals and communities worldwide. 3 3 5 0 630277 0 0 224058 854335 0 0 326274 0 19207 418785 745059 109276 126827 17551 109276 To eliminate the risks posed by pandemic threats through the advancement of science and innovation in medical countermeasure development, ensuring the health and well-being of individuals and communities worldwide. false false 543045 The Synthetic Innate Immunity program aims to develop medicines that serve as society's first line of defense against emerging viral outbreaks by taking inspiration from natural mechanisms of innate immunity. By encoding natural or engineered pattern recognition receptors (PRRs) and interferon-stimulated genes (ISGs) in DNA delivered to the respiratory tract, the program works to persistently enhance a patient's natural sense-and-respond capacity, potentially providing prophylactic protection against a broad range of respiratory viruses for months. During the reporting period, the program achieved several key milestones: developing assays for testing antiviral activities of drug candidates, establishing capacity to deliver nucleic acids to mice, and developing capability to conduct influenza viral challenge studies in mice. 543045 true true false false false false false false false false false false false false false true true false false false false false false false false false false false false false false false false false false false false false true false false false false false false false false true 0 0 false 5 true false false false false false false false 0 false false false false false false false X 3 3 false false true false false false false true true false false true true true true true false true true false CA MA X X Jacob Swett 5854878218 Panoplia Laboratories Inc Cambridge MA 02142 Brian Wang President 40.00 0.00 X 31178 0 2688 William Bradshaw Secretary 0.50 0.00 X X 0 0 0 Jacob Swett Treasurer 0.50 0.00 X X 0 0 0 Ales Flidr Chairman 0.50 0.00 X X 0 0 0 31178 2688 0 false false false 0 630277 100000 630277 0 0 0 0 0 0 0 0 0 Other Income 900099 224058 224058 224058 854335 224058 0 0 0 0 33866 15240 13546 5080 0 255515 213961 30005 11549 0 15371 11389 3054 928 21522 16755 3328 1439 0 30061 30061 0 0 0 0 7024 1258 5766 0 20232 446 19786 5101 131 4970 0 62723 62723 2538 1177 1361 0 0 0 0 0 1098 1098 Research & Development 277000 277000 Dues & Subscriptions 5688 5688 Recruiting & Training 2700 2700 payroll expenses 2357 2357 2263 2052 211 745059 543045 182807 19207 90453 0 0 0 0 0 0 0 36374 0 0 0 0 0 0 0 126827 17551 0 17551 X 109276 0 109276 0 126827 109276 X false true X true false X 630277 630277 0 0 630277 630277 471975 158302 0 0 224058 224058 854335 X 0.00000 RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED X 854335 854335 854335 745059 745059 745059 Part X : FIN48 Footnote The Organization is a not-for-profit organization that has tax-exempt status under the provisions of the Internal Revenue Code section 501(c)(3). Net income from activities unrelated to the Organization's tax-exempt purpose is subject to taxation. The Organization had no significant unrelated business income during 2024, and accordingly, no provision for income taxes has been made in the accompanying financial statements. The Organization annually files IRS Form 990 - Return of Organization Exempt from Income Tax reporting various information that the IRS uses to monitor the activities of tax-exempt entities. There were no tax penalties or interest recognized during the period or accrued at period end. X Equipment 1 100000 Fair Market Value false true false Form 990, Part VI, Section A, Line 4 The organization amended and restated its bylaws on May 16, 2024 (attached). Form 990, Part VI, Section B, Line 11b A copy of the Form 990 was provided to the officers and directors for review and comment prior to filing. Form 990, Part VI, Section B, Line 12c Upon engagement, election, or hiring, directors, officers, and key employees agree to comply with the conflict of interest policy and to disclose any conflicts of interest, which are then handled in accordance with the policy. Form 990, Part VI, Section B, Line 15a It is the organization's policy that compensation of any director, officer, or key employee is reasonable. Accordingly, compensation of the executive director was determined based on relevant comparability data followed by written resolution of a disinterested board approving the compensation in compliance with Treas. Reg. 53.4958-6. Form 990, Part VI, Section B, Line 15b See response to Form 990, Part VI, Line 15a. Form 990, Part VI, Section C, Line 18 The organization's Form 1023 and Form 990 returns are accessible to the public through the California Attorney General Charities Registry. The organization can also make such documents available upon written request. Form 990, Part VI, Section C, Line 19 Documents subject to public disclosure or inspection are accessible through the California Attorney General Charities Registry or can be made available upon written request to the organization.